Core Viewpoint - Veralto has announced the acquisition of GlobalVision, which is expected to enhance its capabilities in quality and compliance solutions for the pharmaceutical and consumer packaged goods sectors [1][4]. Acquisition Details - The acquisition of GlobalVision is subject to customary closing conditions and will be integrated into Veralto's Esko business, leveraging a decade-long partnership [3][4]. - GlobalVision's technology focuses on ensuring packaging accuracy and compliance, which is critical for companies facing regulatory demands [4][10]. - The purchase price for GlobalVision is approximately 15 times its estimated adjusted EBITDA of $13 million, with expected cost synergies to be realized by the end of year two [6]. Financial Information - GlobalVision has experienced a compound annual growth rate of approximately 19% in sales since 2023, with projected sales of about $25 million in 2026, 85% of which is expected to be recurring [5]. - The adjusted EBITDA margin for GlobalVision in 2026 is anticipated to be around 30%, excluding deal-related costs [5]. - The acquisition is expected to be neutral to Veralto's adjusted EPS in 2026 and accretive in 2027 [5]. Share Repurchase Update - In the first quarter of 2026, Veralto repurchased approximately 3.2 million shares for about $300 million, representing around 1.3% of its outstanding shares as of February 13, 2026 [7]. Company Overview - Veralto, with annual sales of approximately $5.5 billion, is a leader in essential technology solutions aimed at addressing complex societal challenges [8]. - The company is committed to safeguarding vital resources and has a global workforce of about 17,000 associates [9].